The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Epic Sciences
Honoraria - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Johnson & Johnson; Merck; NEUVOGEN; Novartis; ORCIC; Regeneron; Sanofi; Turning Point Therapeutics
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Johnson & Johnson; Merck; NEUVOGEN; Novartis; ORCIC; Regeneron; Sanofi; Turning Point Therapeutics
Research Funding - BeyondSpring Pharmaceuticals
KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Roche (Inst); Rubius Therapeutics (Inst); Synthekine (Inst); Takeda (Inst); Trovagene (Inst)
 
Gregory J. Riely
Research Funding - GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Patent application submitted covering pulsatile use of erlotinib to treat or prevent brain metastases (Inst)
Other Relationship - Mirati Therapeutics; Pfizer; Roche/Genentech; Takeda
 
Shirish M. Gadgeel
Honoraria - Merck
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; Daichii-Sanyko; Genentech/Roche; Janssen Oncology; Lilly; Mirati Therapeutics; Novartis; Pfizer; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Blueprint Medicines (Inst); Calithera Biosciences (Inst); Daichii Sanyko (Inst); Daiichi Sankyo (Inst); Dragonfly Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Elevation Oncology (Inst); Erasca, Inc (Inst); Genentech/Roche (Inst); Helsinn Therapeutics (Inst); I-Mab (Inst); Incyte (Inst); InventisBio (Inst); Janssen Oncology (Inst); Merck; Merck (Inst); Mirati Therapeutics (Inst); Nektar (Inst); Nektar (Inst); Numab (Inst); Pfizer (Inst); Regeneron (Inst); Regeneron (Inst); Turning Point Therapeutics (Inst); Verastem (Inst); Ymabs Therapeutics Inc (Inst)
Travel, Accommodations, Expenses - Merck
Other Relationship - AstraZeneca
 
Rebecca Suk Heist
Honoraria - Chugai/Roche
Consulting or Advisory Role - Abbvie; Daichii Sankyo; Daichii Sankyo; EMD Serono/Merck; EMD Serono/Merck; Novartis
Research Funding - Abbvie (Inst); Agios (Inst); Celgene (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Exelixis (Inst); Exelixis (Inst); Incyte (Inst); Lilly (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Turning Point Therapeutics (Inst)
 
Sai-Hong Ignatius Ou
Stock and Other Ownership Interests - Elevation Oncology; Turning Point Therapeutics
Honoraria - ARIAD/Takeda; BeiGene; Caris Life Sciences; Daiichi Sankyo; Dava Oncology; Johnson & Johnson/Janssen; Lilly; Pfizer
Consulting or Advisory Role - BeiGene; Daiichi Sankyo; Elevation Oncology; Janssen; Lilly; Pfizer; Takeda
Speakers' Bureau - Caris Life Sciences
Research Funding - ARIAD (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Janssen (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche Pharma AG (Inst)
 
Jose Maria Pacheco
Honoraria - Genentech/Roche (Inst)
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Blueprint Medicines (Inst); Gerson Lehrman Group; Hengrui Pharmaceutical ; Jazz Pharmaceuticals; Pfizer; Takeda (Inst)
Research Funding - Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; Daiichi Sankyo/UCB Japan; Pfizer; Takeda
 
Melissa Lynne Johnson
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Axelia Oncology (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); EcoR1 Capital (Inst); Editas Medicine (Inst); Eisai (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); IDEAYA Biosciences (Inst); ITeos Therapeutics (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Oncorus (Inst); Regeneron (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); Turning Point Therapeutics (Inst); WindMIL (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Apexigen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Artios (Inst); AstraZeneca (Inst); Atreca (Inst); BeiGene (Inst); BerGenBio (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Carisma Therapeutics (Inst); Checkpoint Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Dynavax Technologies (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immunocore (Inst); IMPAC Medical Systems (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kadmon (Inst); Kartos Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Novartis (Inst); Numab (Inst); Nuvalent, Inc. (Inst); OncoMed (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Stem CentRx (Inst); Syndax (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Turning Point Therapeutics (Inst); University of Michigan (Inst); Vyriad (Inst); WindMIL (Inst); Y-mAbs Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
Joshua K. Sabari
Consulting or Advisory Role - AstraZeneca; Janssen Oncology; Medscape; Navire; Pfizer; Regeneron; Takeda
 
Konstantinos Leventakos
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Mirati Therapeutics (Inst); MJH Life Sciences (Inst); OncLive (Inst); Regeneron (Inst); Takeda (Inst); Targeted Oncology (Inst)
Research Funding - AstraZeneca (Inst); Mirati Therapeutics (Inst)
 
Edwin Yau
No Relationships to Disclose
 
Lyudmila Bazhenova
No Relationships to Disclose
 
Marcelo Vailati Negrao
Consulting or Advisory Role - Merck; Mirati Therapeutics
Research Funding - Alaunos Therapeutics; AstraZeneca; Checkmate Pharmaceuticals; Genentech; Mirati Therapeutics; Novartis; Pfizer; ZIOPHARM Oncology
Other Relationship - Apothecom; Ashfield Healthcare; ZIOPHARM Oncology
 
Nathan A. Pennell
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Cota Healthcare; G1 Therapeutics; Genentech; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Pfizer; Sanofi/Regeneron; Viosera Therapeutics; Xencor
Research Funding - Altor BioScience (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Heat Biologics (Inst); Jounce Therapeutics (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); WindMIL (Inst)
 
Jun Zhang
Consulting or Advisory Role - AstraZeneca; Bayer; Biodesix; Bristol-Myers Squibb; Cardinal Health; Daiichi Sankyo; Hengrui Pharmaceutical; Lilly; MJH Life Sciences; Nexus Health Systems; Novartis; Novocure; Regeneron; Sanofi
Research Funding - Abbvie; AstraZeneca; Biodesix; Genentech/Roche; Hengrui Pharmaceutical; Novartis
 
Karen Velastegui
Employment - Arena Pharma (I); Mirati Therapeutics
Stock and Other Ownership Interests - Arena Pharma (I); Mirati Therapeutics
 
James G Christensen
Employment - Mirati Therapeutics
Leadership - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics
Consulting or Advisory Role - BridgeBio Pharma
Patents, Royalties, Other Intellectual Property - Multiple patents in last 2 years while employed at Mirati Therapeutics covering discovery of KRAS, LSD1, and EZH2 inhibitors. (Inst)
 
xiaohong yan
Employment - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Kenna Lynn Anderes
Employment - Mirati Therapeutics
 
Richard C. Chao
Employment - Mirati Therapeutics
Stock and Other Ownership Interests - Merck; Mirati Therapeutics; Pfizer
 
Pasi A. Janne
Stock and Other Ownership Interests - Gatekeeper Pharmaceuticals; Loxo
Consulting or Advisory Role - Abbvie; Accutar Biotech; Allorion Therapeutics; Araxes Pharma; AstraZeneca; Bayer; Biocartis; Biocartis; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Eisai; Ignyta; Lilly; LOXO; Merrimack; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Pfizer; Roche/Genentech; Sanofi; SFJ Pharmaceuticals Group; Silicon Therapeutics; Syndax; Takeda; Transcenta; Voronoi Health Analytics
Research Funding - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Lilly; Puma Biotechnology; Revolution Medicines; Takeda
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp. I receive post-marketing royalties from this invention